MEC Plus – MyMedflix Member Portal

Skip to content

Live Events

Live Events

Live Events

Live Events

MEC Plus

Events

Speciality

Type of Media

Author / Speaker

Title

Search Entries:

«
1
…
40
41
42
43
44
…
100
»

Navigating Payor Barriers to Access of Oncology Pharmaceuticals: Real-World Case Approach

Navigating Payor Barriers to Access of Oncology Pharmaceuticals: Real-World Case Approach

Jorge Garcia, PharmD, MS, MHA, MBA, FACHE

The Art-of-Medicine in Treating Chronic Lymphocytic Leukemia

The Art-of-Medicine in Treating Chronic Lymphocytic Leukemia

Javier Pinilla-Ibarz, MD

Follicular Lymphoma: Defining Best 1L and 2L Treatment in the Era of Personalized Medicine

Follicular Lymphoma: Defining Best 1L and 2L Treatment in the Era of Personalized Medicine

Nakhle Saba, MD

Novel Therapeutic Advances for DLBCL & Hodgkin’s Disease

Novel Therapeutic Advances for DLBCL & Hodgkin’s Disease

Eduardo Sotomayor, MD

T-Cell NHL: Novel Approaches & Challenges

T-Cell NHL: Novel Approaches & Challenges

Francine M. Foss, MD

ADC in NSCLC: CEACAM5 and Teliso-V

ADC in NSCLC: CEACAM5 and Teliso-V

Julia Rotow, MD

ADC in NSCLC: TROP2 and HER3 in NSCLC

ADC in NSCLC: TROP2 and HER3 in NSCLC

Hossein Borghaei, MD

EGFRex20ins, METex14 and RET in NSCLC

EGFRex20ins, METex14 and RET in NSCLC

Mark Socinski, MD

K-RAS and ERBB2 Mutation in NSCLC

K-RAS and ERBB2 Mutation in NSCLC

Yasir Elamin, MD

Neoadjuvant and Adjuvant Immunotherapy in Early Stage Lung Cancer

Neoadjuvant and Adjuvant Immunotherapy in Early Stage Lung Cancer

Karen Kelly, MD

Novel Treatment for Unresectable Stage III NSCLC

Novel Treatment for Unresectable Stage III NSCLC

Edgardo S. Santos Castillero, MD, FACP

Small Cell Lung Cancer: 1L and Beyond

Small Cell Lung Cancer: 1L and Beyond

Anne Chiang, MD

Identifying and Targeting Mechanisms of Resistance to 3rd Generation EGFR Inhibitors

Identifying and Targeting Mechanisms of Resistance to 3rd Generation EGFR Inhibitors

Ravi Salgia, MD

ALK: Choosing 1L & Mechanism of Resistance

ALK: Choosing 1L & Mechanism of Resistance

Ibiayi Dagogo-Jack, MD

Novel Advances in Mesothelioma

Novel Advances in Mesothelioma

Jorge E. Gomez, MD

Pre-Operative and Metastatic Setting Biomarkers for Immunotherapy in Lung Cancer

Pre-Operative and Metastatic Setting Biomarkers for Immunotherapy in Lung Cancer

Fred Hirsch, MD

ctDNA in Lung Cancer: Current State and Future Perspectives

ctDNA in Lung Cancer: Current State and Future Perspectives

Bruna Pellini, MD

Drug Development and New Targeted Agents for Breast Cancer: What Does the Future Hold?

Drug Development and New Targeted Agents for Breast Cancer: What Does the Future Hold?

Mark Pegram, MD

Sequencing Endocrine Therapy and Targeted Agents for the Treatment of Metastatic HR+/HER2- Breast Cancer

Sequencing Endocrine Therapy and Targeted Agents for the Treatment of Metastatic HR+/HER2- Breast Cancer

Neelima Vidula, MD

Optimal Treatment for Early Stage HER2 Positive Breast Cancer: Tailoring Treatment to Response

Optimal Treatment for Early Stage HER2 Positive Breast Cancer: Tailoring Treatment to Response

Virginia Borges, MD

Immunotherapy for Breast Cancer: Current and Future Directions

Immunotherapy for Breast Cancer: Current and Future Directions

Heather McArthur, MD

Changing Delivery of Chemotherapy for Breast Cancer: The Broad Impact of Antibody Drug Conjugates

Changing Delivery of Chemotherapy for Breast Cancer: The Broad Impact of Antibody Drug Conjugates

Hope Rugo, MD, FASCO

Survivorship in the Modern Era of Cancer Care: Goals, Measures, and Outcomes

Survivorship in the Modern Era of Cancer Care: Goals, Measures, and Outcomes

Adrienne M. Vazquez Guerra, MSN, ACNP-BC, AOCN

Management of Osteonecrosis of Jaw and Other Complications from Bisphosphonate and/or RANK Ligand Inhibitors

Management of Osteonecrosis of Jaw and Other Complications from Bisphosphonate and/or RANK Ligand Inhibitors

Robert E. Marx, DDS, FACS

Telemedicine in Oncology

Telemedicine in Oncology

Jack West, MD

Medical Marijuana: Who, When & How?

Medical Marijuana: Who, When & How?

Dov Pickholtz, DO

Melanoma: What is after immunotherapy? More immunomodulation?

Melanoma: What is after immunotherapy? More immunomodulation?

Sanjiv Agarwala, MD

Toxicities in Immunotherapy

Toxicities in Immunotherapy

Mayra A. Lima, ARNP, MSN, FNP-C

Immunotherapy and Other Systemic Therapy in Gynecologic Malignancies

Immunotherapy and Other Systemic Therapy in Gynecologic Malignancies

Gerardo Colon-Otero, MD

Immunotherapy in Kidney & Bladder Cancer

Immunotherapy in Kidney & Bladder Cancer

Rohit Jain, MD

Displaying 1,231 - 1,260 of 2,995

«
1
…
40
41
42
43
44
…
100
»

6619 South Dixie Highway #341
Miami, FL 33143

Phone: 305.663.1628
Email: info@meccinc.com

Userful Links

Live Events

Categories

About Us

Why Subscribe
About Us
Accreditation

© 2025 MEC Inc. All rights reserved | Digital Marketing by Katapult Marketing

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok